Recurrent benign fibrous histiocytoma of the bone benefits from denosumab followed by malignant transformation: a case report.

IF 1.9 3区医学 Q2 ORTHOPEDICS

Skeletal Radiology Pub Date : 2024-11-01 Epub Date: 2024-02-19 DOI:10.1007/s00256-024-04610-w

Wetterwald Laureline, Omoumi Patrick, Nguyen Tu, Cherix Stephane, Dolcan Ana, Ferraro Daniela, Saglietti Chiara, Letovanec Igor, Digklia Antonia

引用次数: 0

Abstract

Benign fibrous histiocytoma of the bone (BFHB) is a rare mesenchymal tumor, representing less than 1% of all benign bone tumors. This controversial entity is characterized by a mixture of fibroblasts arranged in a storiform pattern, varying amounts of osteoclast-type giant cells and foamy macrophages. Curettage or simple resection is usually curative. However, it was reported that up to 11% of the patients suffer from relapse. Here, we report a case of malignant transformation of BFHB after long-lasting disease stabilization under denosumab therapy.

查看原文本刊更多论文

复发性骨良性纤维组织细胞瘤受益于地诺单抗后发生恶性转化：病例报告。

良性骨纤维组织细胞瘤（BFHB）是一种罕见的间叶肿瘤，在所有良性骨肿瘤中占比不到 1%。这种有争议的肿瘤的特征是成纤维细胞、不同数量的破骨细胞型巨细胞和泡沫状巨噬细胞混合排列成storiform模式。刮宫或简单切除通常可以治愈。然而，据报道，多达 11% 的患者会复发。在此，我们报告了一例在接受地诺单抗治疗后病情长期稳定的 BFHB 恶性转化病例。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Skeletal Radiology 医学-核医学

CiteScore

4.40

自引率

9.50%

发文量

253

审稿时长

3-8 weeks

期刊介绍： Skeletal Radiology provides a forum for the dissemination of current knowledge and information dealing with disorders of the musculoskeletal system including the spine. While emphasizing the radiological aspects of the many varied skeletal abnormalities, the journal also adopts an interdisciplinary approach, reflecting the membership of the International Skeletal Society. Thus, the anatomical, pathological, physiological, clinical, metabolic and epidemiological aspects of the many entities affecting the skeleton receive appropriate consideration. This is the Journal of the International Skeletal Society and the Official Journal of the Society of Skeletal Radiology and the Australasian Musculoskelelal Imaging Group.